Avid Bioservices Inc (CDMO)

[sunstar]

mojo, Thanks for the straight-talk phase2 ECOG details showing the disadvantage that the 3mg/kg Bavi arm faced and surmounted, to still, more than double the patient survival MOS in advanced NSCLC. I think that the incredible challenge that PPHM faced in the phase2 trial, and their successful salvaging of the data that was interfered with by a third party, bodes well for Bavituximab's phase3 trial, and an easy FDA approval for Bavi.

As the SUNRISE trial heads toward full enrolment, my sense is that the risk for PPHM investors is rapidly diminishing.

IMO

sunstar